Back To Normal-ish: What To Expect As Pharma Resumes In-Person Gatherings

With the mask mandate now lifted for air travel and the grimmer milestone of one million Americans dead from COVID approaching, the Pink Sheet looks back at the generic trade association’s annual meeting to see what business gatherings may look like going forward.

THIS WAS THE FIRST IN-PERSON ANNUAL MEETING FOR AAM CEO DAN LEONARD, WHO JOINED THE TRADE GROUP IN AUGUST 2020.
THIS WAS THE FIRST IN-PERSON ANNUAL MEETING FOR AAM CEO DAN LEONARD, WHO JOINED THE TRADE GROUP IN AUGUST 2020. • Source: Nielsen Hobbs

Multinational corporations bemoaned their underdog status and Doug Long made a Yogi Berra joke. If it hadn’t been for the hotel staff in masks and the six-piece “protection kit” at every chair, the Association for Accessible Medicines’ annual meeting in Orlando earlier this year might have seemed unchanged, despite the two-year break from the gathering imposed by COVID.

With the mask mandate now lifted for airflights and the grimmer milestone of one million Americans dead from COVID approaching,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

‘Prescription Drugs Are Not Golf Balls’: FTC/DoJ Solicit Clashing Opinions On Patents

 

Innovator drug advocates argued that the number of patents asserted by industry is not too dissimilar to other fields. But should drugs be compared to golf balls?

ANDA User Fees: Complex Generics, Transparency, Communications Are Early Negotiation Targets

 
• By 

Teva seeks a dedicated development program and first-cycle approval metrics for complex generics. Role of artificial intelligence in the generic drug review process is a talking point for both agency and industry at reauthorization kickoff meeting.

US FDA Will Not Pull Teva And MSN Hetlioz ANDAs, Rejects Vanda Citizen Petitions

 
• By 

The FDA concluded that generic tasimelteon products held by Teva and MSN Labs meet all statutory bioequivalence requirements and there was no “mistake” or untrue statement in the original ANDA approvals.

US Supreme Court Wants Solicitor General Input On Hikma Skinny Label Case

 
• By 

The US Supreme Court is seeking the administration's view following the Federal Circuit decided to reopen Amarin’s case against the ‘skinny-label’ generic Vascepa (icosapent ethyl).

More from Conferences

Post-BIO Podcast: Thoughts From The Frontlines

Pink Sheet and Scrip journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

BIO CEO On Industry And US FDA, Trump’s Vaccine Views And MFN Counter Proposals

 

John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

 
• By 

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.